DRI
60
6
LYB
32
3
NSC
50
3
BMY
32
2
MMM
28
3
KMX
55
2
MOS
29
6
HOG
29
-7
FRT
46
8
BAC
50
6
AFL
63
3
GILD
26
2
TRV
49
-4
CCI
46
4
UHS
66
2
UNP
45
7
PGR
70
5
XOM
50
6
BRK.B
42
6
BK
66
5
DRI
60
6
LYB
32
3
NSC
50
3
BMY
32
2
MMM
28
3
KMX
55
2
MOS
29
6
HOG
29
-7
FRT
46
8
BAC
50
6
AFL
63
3
GILD
26
2
TRV
49
-4
CCI
46
4
UHS
66
2
UNP
45
7
PGR
70
5
XOM
50
6
BRK.B
42
6
BK
66
5
Financhill
Back

EyePoint Pharmaceuticals Quote, Financials, Valuation and Earnings

Sell
43

EYPT
EyePoint Pharmaceuticals

Last Price:
10.70
Seasonality Move:
-1.61%

7 Day Trial

ALL ACCESS PASS

$ 7

EyePoint Pharmaceuticals Price Quote

$10.70
-0.01 (-0.47%)
(Updated: June 1, 2024 at 6:18 AM ET)

EyePoint Pharmaceuticals Key Stats

Sell
43
EyePoint Pharmaceuticals (EYPT) is a Sell
Day range:
$10.41 - $10.89
52-week range:
$5.67 - $30.99
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
9.16
P/B ratio:
2.23%
Volume:
1.1M
Avg. volume:
1.4M
1-year change:
77.02%
Market cap:
$557.8M
Revenue:
$46M
EPS:
$-1.81

How Much Does EyePoint Pharmaceuticals Make?

Is EyePoint Pharmaceuticals Growing As A Company?

EyePoint Pharmaceuticals Stock Price Performance

What Is EyePoint Pharmaceuticals 52-Week High & Low?

EyePoint Pharmaceuticals Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy EyePoint Pharmaceuticals?

Is EyePoint Pharmaceuticals Cash Flow Positive?

  • What Is EYPT Cash Flow From Operations?
    Cash flow from operations (TTM) is -$12.5M
  • What Is EyePoint Pharmaceuticals’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $192.3M
  • What Is EyePoint Pharmaceuticals’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$14.6M

EyePoint Pharmaceuticals Return On Invested Capital

  • Is Management Doing A Good Job?
    EYPT return on invested capital is -52.95%
  • What Is EyePoint Pharmaceuticals Return On Assets?
    ROA measures how assets are converting to revenues and is -33.59%
  • What Is EYPT Return On Equity?
    ROE is a measure of profitability and is -55.53%

EyePoint Pharmaceuticals Earnings Date & Stock Price

EyePoint Pharmaceuticals Competitors

EyePoint Pharmaceuticals Dividend Yield

Data Unavailable

EyePoint Pharmaceuticals Analyst Estimates

YoY Growth Past Surprise
EPS: 0% -29.54%
Revenue: 52.08% 27.9%

Analyst Recommendations

Buy Recommendations: 7
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 39.11
Upside from Last Price: 265.18%

Major Shareholders

  • How many EYPT shares are owned by institutional investors?
    81.9M EYPT shares are owned by institutional investors
  • How many EYPT shares are owned by insiders?
    1.4M EYPT shares are owned by insiders